Serum Institute applies for full marketing authorisation of Covishield

Vaccine accounts for 88 per cent of all the Covid-19 jabs given in India.

Serum Institute of India (SII) has applied for a full marketing authorization for its Covid-19 vaccine, said company CEO Adar Poonawalla on Friday.

“Supplies of the COVISHIELD vaccine in India, have exceeded 1.25 billion doses. The government of India now has enough data for full market authorisation, and therefore @SerumInstIndia has applied to the @CDSCO_INDIA_INF (DCGI) and @MoHFW_INDIA for this permission,” Poonawalla said on Twitter.

Covishield received a restricted emergency use authorisation in January this year. Seurum has the capacity to make 250 million doses of Covishield monthly. The vaccine has accounted for 88 per cent of all the Covid-19